Targeting genomic instability: From chemotherapy to precision medicine in cancer treatment
By
Timothy A. Yap1,6 Send email to [email protected]
Crisp on the outside, thoughtful on the inside. A keeper.
Summary
This article examines genomic instability as a hallmark of cancer, explaining how it drives malignant transformation through accumulated genetic and epigenetic alterations. It traces the evolution of treatments targeting this instability, from systemic chemotherapy and radiation to PARP inhibitors for homologous recombination repair-deficient tumors, and more recently to antibody-drug conjugates and radiopharmaceuticals. The piece emphasizes that precision medicine now focuses on patient selection and rational drug combinations to expand the therapeutic index and improve outcomes.
Key quotes
· 4 pulledGenomic instability is a defining feature of cancer, which arises when the cellular systems that maintain DNA integrity falter
It is both the architect of cancer's evolution and its Achilles' heel
Targeting genomic instability has reshaped oncology: first through systemic chemotherapy and external beam radiation and then with poly(ADP-ribose) polymerase (PARP) inhibitors
Precision medicine targeting genomic instability now emphasizes patient selection and rational drug combinations, expanding the therapeutic index for better outcomes
You might also wanna read
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment
economist.com·12h ago
New CRISPR Technique Selectively Destroys Cancer Cells with Common Mutation
Researchers at UC Berkeley, UCSF, and Gladstone Institutes have developed a novel CRISPR-based technique called "RNA-Triggered Chromatin Shr
innovativegenomics.org·1d agoAsk HN: What is the latest on treatment of Metastatic Breast Cancer?
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·9mo ago
AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
The article discusses recent advancements in AI-driven drug discovery, highlighting two key developments: 1) Analytica 2026, an event focuse
drugtargetreview.com·4mo ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago